Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD: A Prospective, Multicenter Study With Randomization in Treatment-Naïve Patients and Switch in Pretreated Patients

NCT07794514 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.

NCT NCT07794514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07794514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD: A Prospective, Multicenter Study With Randomization in Treatment-Naïve Patients and Switch in Pretreated Patients
Lead sponsor
First Affiliated Hospital of Zhejiang University
Phase
Not applicable
Overall status
Recruiting
Start date
October 1, 2026
Completion date
December 31, 2030
Enrollment
170 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

belumosudil, cgvhd, hematopoietic stem cell transplantation (hsct), hepatic cgvhd, ruxolitinib